Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 86 Florida 71 Colorado 40 Massachusetts 40 Texas 40
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Pfizer3 Novartis Pharmaceuticals3 AstraZeneca2 Alterome Therapeutics, Inc.1 Biotheryx, Inc.1
State
California86 Florida71 Colorado40 Massachusetts40 Texas40
All 47 states
Target enrolment
to

Trials with a site in Texas

40 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
Regor Pharmaceuticals Inc.
Phase 1
63
California, Texas, Virginia
2026-06
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
175
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
NCT07206121Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu
Innoblative Designs, Inc.
Not applicable
10
Texas
2026-02-10
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
NCT07505797Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms
iSono Health, Inc.
Observational
800
California, Texas
2025-12-16
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
DrugBG-75202
BeOne Medicines
Phase 1
86
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
DrugsTrastuzumab·Cetuximab
Fate Therapeutics
Phase 1
119
California, Minnesota, Pennsylvania, Texas
2025-11-04
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
DrugDato-DXd
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study
NCT07318051Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
Natera, Inc.
Observational
9,600
Texas
2025-07-21
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
DrugZelenectide pevedotin
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
Evaluation of the Bexa Breast Examination
NCT06643767Breast Cancer
Sure, Inc.
Not applicable
500
Texas
2024-10-16
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Active, closed
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Capecitabine
Novartis Pharmaceuticals
Phase 1/2
20
California, Minnesota, Texas, Wisconsin
2024-08-14
Recruiting
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT06515470Breast Cancer
DrugFulvestrant
Biotheryx, Inc.
Phase 1
82
Minnesota, Nebraska, Texas, Utah, Virginia
2024-07-03
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
285
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
California, Florida, Missouri, New Jersey, South Dakota, Texas
2024-03-11
Active, closed
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Breast Cancer
DrugsVepdegestrant·Atirmociclib
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1
28
California, Texas
2023-11-13
Recruiting
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
NCT06085833Breast Cancer
ARTIDIS AG
Not applicable
2,706
Texas, Washington
2023-11-02
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.
Phase 1
165
California, Massachusetts, Tennessee, Texas
2023-09-14
Active, closed
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127Breast Cancer
DrugsVepdegestrant·Abemaciclib
Pfizer
Phase 1/2
37
California, Florida, Illinois, Missouri, Texas, Washington
2023-02-23
Active, closed
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532Breast Cancer
Accutar Biotechnology Inc
Phase 1
100
Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington
2022-12-29
Active, closed
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752Non Small Cell Lung Cancer, Breast Cancer
DrugYL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Florida, Michigan, Texas, Virginia, Washington
2022-12-20
Recruiting
Comprehensive Outcomes for After Cancer Health
NCT05349227Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
Pack Health
Not applicable
625
Florida, Massachusetts, Nebraska, New York, Ohio, Texas
2022-06-23
Active, closed
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714Advanced Solid Tumor, Breast Cancer
DrugsCFI-402257·Fulvestrant
Treadwell Therapeutics, Inc
Phase 1/2
44
Ohio, Texas, Utah, Virginia
2022-05-27
Active, closed
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
DrugsKeytruda·Pembrolizumab
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Active, closed
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400Breast Cancer, Solid Tumors
DrugsPF-07104091·Atirmociclib
Pfizer
Phase 1/2
235
California, Massachusetts, Michigan, Missouri, Texas, Washington
2022-03-14
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
New York, Texas, Washington
2021-07-16
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Dato-DXd·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
Tempus Priority Study: A Pan-tumor Observational Study
NCT05179824Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
Tempus AI
Observational
1,000
Texas
2020-10-19
Recruiting
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT04503265Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
DrugExpansion
AtlasMedx, Incorporated
Phase 1/2
122
California, Maryland, Tennessee, Texas
2020-08-12
Active, closed
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701Breast Cancer, Non-small Cell Lung Carcinoma
DrugsTrastuzumab deruxtecan·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 1
115
California, Connecticut, Florida, Maryland, Massachusetts, Missouri, Pennsylvania, Texas
2020-02-10
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
DrugsInavolisib·Palbociclib·Fulvestrant
Hoffmann-La Roche
Phase 2/3
325
California, Massachusetts, New York, North Carolina, Tennessee, Texas, Washington
2020-01-29
Recruiting
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT03796559Breast Cancer, Axillary Lymph Nodes
Endomagnetics Ltd.
Not applicable
65
Texas
2019-06-13
Active, closed
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
NCT02955940Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
DrugsRegorafenib·Xeloda·Ruxolitinib·Capecitabine
Incyte Corporation
Phase 2
10
California, Kentucky, New York, Tennessee, Texas
2016-11-30
Active, closed
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
NCT01872260Breast Cancer
DrugsAlpelisib·Ribociclib·Letrozole
Novartis Pharmaceuticals
Phase 1/2
259
California, Florida, Massachusetts, Tennessee, Texas, Washington
2013-10-22
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

20 of the 40 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 40 studies
PhaseStudiesRecruitingShare
Phase 115637.5%
Phase 1/211427.5%
Not applicable5512.5%
Observational4310%
Phase 2317.5%
Phase 2/3102.5%
Phase 3112.5%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals30
Pfizer30
AstraZeneca21
Accutar Biotechnology Inc10
Alterome Therapeutics, Inc.10
ARTIDIS AG11
Atavistik Bio, Inc10
AtlasMedx, Incorporated11
Avacta Life Sciences Ltd10
BeiGene10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.